Company intelligence
DeepLife
AI for digital twin of cells
About DeepLife
DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.
Verified activity
Signals from DeepLife
2 published signals
Presence & Recognition
DeepLife is heading to Biotech Week Boston to attend RESI Boston on 22–23 September and LSX Congress USA on 23–24 September.
Reported by DeepLife
Presence & Recognition
DeepLife Head of Drug Discovery Yann Abraham will speak at the Drug Discovery Innovation Programme (DDIP) Europe in Basel on 30 September to discuss Target Identification with Virtual Cells using Large Causal Cell Models in Early Drug Discovery.
Reported by DeepLife